Piperlongumine

ID: piperlongumine

Aliases: PL, long pepper alkaloid

Type: compound

Route/form: oral/supplement-like natural product in discussion; studied mainly in vitro/preclinical

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 2

Broad outcomes: Gut / immune / inflammation, Longevity / mitochondrial / redox

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• senescent cell apoptosis
• senolytic lead
• redox and stress-response pathways

Optimization domains

• anti aging
• senolytic
• cancer biology
• redox
• inflammation
• natural product

Research basis

• A direct senolytic discovery paper reports preferential killing of senescent human fibroblasts and synergy with ABT-263.
• It belongs as a speculative senolytic lead with a concrete paper trail rather than a generic antioxidant/natural-product claim.

Limits, risks, and missing evidence

• The senolytic case is mainly cell/preclinical work and should not be treated as human anti-aging efficacy.
• Cytotoxic and cancer-biology mechanisms make casual supplement extrapolation especially weak.

Risk flags

• preclinical only
• cytotoxicity
• oncology context
• limited human data
• standardization uncertainty
• translational gap

Linked papers, labels, and reviews

1. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents
   preclinical / pmc_piperlongumine_senolytic_2016
   Direct senolytic-discovery paper for piperlongumine; mostly cellular/preclinical and not human anti-aging evidence.
2. Senolytic drugs: from discovery to translation
   review / pmc_senolytics_translation_review_2020
   Translational senolytics review that contextualizes piperlongumine among senescent-cell targeting leads and caveats.